NO321504B1 - Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. - Google Patents
Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. Download PDFInfo
- Publication number
- NO321504B1 NO321504B1 NO19975832A NO975832A NO321504B1 NO 321504 B1 NO321504 B1 NO 321504B1 NO 19975832 A NO19975832 A NO 19975832A NO 975832 A NO975832 A NO 975832A NO 321504 B1 NO321504 B1 NO 321504B1
- Authority
- NO
- Norway
- Prior art keywords
- protein hydrolyzate
- casein
- composition
- preparation
- lactobacillus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 239000003531 protein hydrolysate Substances 0.000 title claims description 30
- 238000002360 preparation method Methods 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 17
- 238000000338 in vitro Methods 0.000 title claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 48
- 229940039696 lactobacillus Drugs 0.000 claims description 42
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 enzyme Drugs 0.000 claims description 19
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 206010020751 Hypersensitivity Diseases 0.000 claims description 14
- 102000057297 Pepsin A Human genes 0.000 claims description 14
- 108090000284 Pepsin A Proteins 0.000 claims description 14
- 102000004142 Trypsin Human genes 0.000 claims description 14
- 108090000631 Trypsin Proteins 0.000 claims description 14
- 229940111202 pepsin Drugs 0.000 claims description 14
- 239000012588 trypsin Substances 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 230000000968 intestinal effect Effects 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 208000009793 Milk Hypersensitivity Diseases 0.000 claims description 11
- 201000010859 Milk allergy Diseases 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 11
- 230000004888 barrier function Effects 0.000 claims description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 230000010585 negative regulation of hypersensitivity Effects 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 230000003614 tolerogenic effect Effects 0.000 claims description 4
- 239000005018 casein Substances 0.000 description 55
- 235000013350 formula milk Nutrition 0.000 description 31
- 102000011632 Caseins Human genes 0.000 description 26
- 108010076119 Caseins Proteins 0.000 description 26
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 26
- 235000021240 caseins Nutrition 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 18
- 206010012438 Dermatitis atopic Diseases 0.000 description 15
- 201000008937 atopic dermatitis Diseases 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 235000020247 cow milk Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- 206010003645 Atopy Diseases 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 239000005862 Whey Substances 0.000 description 7
- 102000007544 Whey Proteins Human genes 0.000 description 7
- 108010046377 Whey Proteins Proteins 0.000 description 7
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 7
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 7
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108010047620 Phytohemagglutinins Proteins 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000001885 phytohemagglutinin Effects 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000020614 extensively hydrolysed formula Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000017307 interleukin-4 production Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000004673 intestinal mucosal barrier function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000020883 elimination diet Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004094 preconcentration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI952926A FI104465B (fi) | 1995-06-14 | 1995-06-14 | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
PCT/FI1996/000350 WO1997000078A1 (en) | 1995-06-14 | 1996-06-12 | Methods of preventing or treating allergies |
Publications (3)
Publication Number | Publication Date |
---|---|
NO975832D0 NO975832D0 (no) | 1997-12-11 |
NO975832L NO975832L (no) | 1997-12-11 |
NO321504B1 true NO321504B1 (no) | 2006-05-15 |
Family
ID=8543602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19975832A NO321504B1 (no) | 1995-06-14 | 1997-12-11 | Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. |
Country Status (27)
Country | Link |
---|---|
US (2) | US6506380B1 (de) |
EP (1) | EP0833649B2 (de) |
JP (1) | JP3983804B2 (de) |
KR (1) | KR100494741B1 (de) |
CN (1) | CN1154506C (de) |
AR (1) | AR003960A1 (de) |
AT (1) | ATE230606T1 (de) |
BG (1) | BG63153B1 (de) |
BR (1) | BR9607827A (de) |
CA (1) | CA2224320C (de) |
CZ (1) | CZ291904B6 (de) |
DE (1) | DE69625690T3 (de) |
DK (1) | DK0833649T4 (de) |
EE (1) | EE03424B1 (de) |
ES (1) | ES2191103T5 (de) |
FI (1) | FI104465B (de) |
HK (1) | HK1010081A1 (de) |
IL (1) | IL122577A0 (de) |
MX (1) | MX9710109A (de) |
MY (1) | MY113912A (de) |
NO (1) | NO321504B1 (de) |
NZ (1) | NZ310478A (de) |
PL (1) | PL185123B1 (de) |
RO (1) | RO120243B1 (de) |
SK (1) | SK284245B6 (de) |
WO (1) | WO1997000078A1 (de) |
ZA (1) | ZA965088B (de) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
EP0986314B1 (de) * | 1997-06-03 | 2008-09-10 | Ganeden Biotech, Inc. | Probiotisches milchsäurebakterium zur behandlung bakterieller infektionen in zusammenhang mit sids |
IL138002A0 (en) | 1999-01-19 | 2001-10-31 | Maxygen Inc | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
CA2378426C (en) | 1999-08-05 | 2010-03-23 | Societe Des Produits Nestle S.A. | Bifidobacteria capable of preventing diarrhea |
TR200200301T2 (tr) | 1999-08-05 | 2004-12-21 | Societe Des Produits Nestle S.A. | Patojenik bakterilerin sebep olduğu ishali ölemeye elverişli bifidobakteriler |
WO2001057534A2 (en) * | 2000-02-04 | 2001-08-09 | Bioseek | Compositions and methods for reducing autoimmunity |
FI110668B (fi) | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
MXPA03001673A (es) * | 2000-09-25 | 2003-06-09 | Nestle Sa | Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas. |
EP1593382A1 (de) | 2000-10-06 | 2005-11-09 | Société des Produits Nestlé S.A. | Verwendung von probiotische Milchsäure-produzierende Bakterien zur Beeinflüssung des Immunsystems der Haut |
FI109602B (fi) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probioottiyhdistelmä |
EP1228707A1 (de) * | 2001-02-01 | 2002-08-07 | Campina Melkunie B.V. | Verwendung von alpha-lactalbumin als praebiotischer Wirkstoff |
CA2439078C (en) * | 2001-03-09 | 2009-08-25 | Societe Des Produits Nestle S.A. | Composition improving age-related physiological deficits and increasing longevity |
JP2003137804A (ja) * | 2001-10-31 | 2003-05-14 | Morinaga Milk Ind Co Ltd | インターロイキン−18誘導剤 |
EP1364586A1 (de) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotika und Oraltoleranz |
JP4376180B2 (ja) | 2002-06-04 | 2009-12-02 | ディーエスエム アイピー アセッツ ビー.ブイ. | トリペプチドに富むタンパク水解物 |
ATE402993T1 (de) | 2002-06-28 | 2008-08-15 | Puleva Biotech Sa | Probiotische stämme, verfahren zur ihren selektion, diese enthaltende zusammensetzungen und ihre verwendung |
EP1384483A1 (de) | 2002-07-23 | 2004-01-28 | Nestec S.A. | Probiotische Mikroorganismen zur Behandlung von Colon Irritabile durch die Verbesserung der neuromuskulären Darmfunktion |
US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
CN1863463B (zh) | 2003-06-23 | 2011-05-04 | 雀巢技术公司 | 用于促进肠道屏障成熟的营养组合物 |
CA2556736C (en) | 2004-02-25 | 2013-02-19 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof |
US20050265946A1 (en) * | 2004-05-28 | 2005-12-01 | Kao Corporation | Elastase inhibitor |
US7862808B2 (en) | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
MX2007012697A (es) | 2005-04-13 | 2008-01-14 | Nestec Sa | Formula para infantes con probioticos. |
US7303745B2 (en) | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
BRPI0618569A2 (pt) * | 2005-11-14 | 2011-09-06 | Nestec Sa | promoção de toleráncia oral com proteìnas glicadas |
CN101420965B (zh) | 2006-02-15 | 2013-08-07 | 雀巢产品技术援助有限公司 | 长双歧杆菌在制备预防和治疗炎症的药物中的用途 |
MY149913A (en) | 2006-03-07 | 2013-10-31 | Nestec Sa | Synbiotic mixture |
BRPI0713596A2 (pt) * | 2006-06-15 | 2012-10-30 | Nestec Sa | indução de toleráncia às proteìnas do ovo |
RU2468808C2 (ru) * | 2007-02-28 | 2012-12-10 | Мид Джонсон Нутришен Компани | Способ лечения или предотвращения системного воспаления |
EP1974735A1 (de) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Verringerung des Durchfallrisikos |
CN101273738B (zh) * | 2007-03-28 | 2011-06-01 | 哈尔滨正方科技有限公司 | 在常温下保持高活菌数的调配型酸性乳饮料的制备方法 |
EP1974743A1 (de) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotika zur Verbesserung der Darm-Biozönose |
EP1974734A1 (de) † | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotika zur Minderung des Risikos von Fettleibigkeit |
US7977078B2 (en) | 2007-08-24 | 2011-07-12 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
EP2072052A1 (de) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Verhinderung opportunistischer Infektionen bei Personen mit schwachem Immunsystem |
CA2712207A1 (en) | 2008-01-24 | 2009-07-30 | Nestec S.A. | Capsule containing nutritional ingredients and method of delivery of a nutritional liquid from the capsule |
DK2244734T3 (en) | 2008-02-01 | 2016-08-15 | Murdoch Childrens Res Inst | PROCEDURE FOR INDUCTION OF TOLERANCE ABOUT AN ALLERGY |
PT2265135T (pt) | 2008-03-14 | 2018-02-21 | Nestec Sa | Mistura simbiótica |
EP2127661A1 (de) | 2008-05-27 | 2009-12-02 | Nestec S.A. | Probiotika zur Verbesserung der Darm-Biozönose |
ES2575005T3 (es) | 2008-06-13 | 2016-06-23 | Codexis, Inc. | Método de síntesis de variantes de polinucleótidos |
US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
MX2010014500A (es) | 2008-06-24 | 2011-05-30 | Codexis Inc | Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros. |
EP2147678A1 (de) | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotika zur Erhöhung der IgA-Sekretion bei per Kaiserschnitt geborenen Kindern |
US8426178B2 (en) | 2008-08-27 | 2013-04-23 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
SG172891A1 (en) | 2009-01-08 | 2011-08-29 | Codexis Inc | Transaminase polypeptides |
WO2010107644A2 (en) | 2009-03-17 | 2010-09-23 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
BRPI1010239A2 (pt) | 2009-03-31 | 2016-10-11 | Codexis Inc | endoglucanases aprimoradas, derivados e seus usos |
CA2762616C (en) | 2009-06-16 | 2015-08-18 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
CN102482648B (zh) | 2009-06-22 | 2014-12-10 | 科德克希思公司 | 酮还原酶介导的产生α氯代醇的立体选择性途径 |
WO2011011630A2 (en) | 2009-07-23 | 2011-01-27 | Codexis, Inc. | Nitrilase biocatalysts |
IN2012DN00878A (de) * | 2009-08-18 | 2015-05-22 | Nestec Sa | |
MX341971B (es) * | 2009-08-18 | 2016-09-08 | Nestec Sa | Una composicion nutricional que comprende cepas de bifidobacterium longum y que reduce los sintomas de la alergia a los alimentos, especialmente en lactantes y niños. |
WO2011022548A2 (en) | 2009-08-19 | 2011-02-24 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US8785170B2 (en) | 2009-09-04 | 2014-07-22 | Codexis, Inc. | Variant CBH2 cellulases and related polynucleotides |
EP2295535A1 (de) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotisches Material |
EP2478137B1 (de) | 2009-09-18 | 2017-09-13 | Codexis, Inc. | Reduzierte codon-mutagenese |
CA2781399C (en) | 2009-11-25 | 2015-01-20 | Codexis, Inc. | Recombinant thermoascus aurantiacus beta-glucosidase variants for production of fermentable sugars from cellulosic biomass |
WO2011066457A2 (en) | 2009-11-25 | 2011-06-03 | Codexis, Inc. | Recombinant beta-glucosidase variants for production of soluble sugars from cellulosic biomass |
AU2010329990B2 (en) | 2009-12-08 | 2015-07-16 | Nestec S.A. | Infant formula with probiotics and milk fat globule membrane components |
CN102884178B (zh) | 2009-12-08 | 2014-12-03 | 科德克希思公司 | 拉唑化合物的合成 |
MX2012007681A (es) | 2009-12-31 | 2013-01-29 | Pioneer Hi Bred Int | Ingenieria de resistencia de plantas a enfermedades causadas por patogenos. |
EP2566497B1 (de) | 2010-05-04 | 2015-07-29 | Codexis, Inc. | Biokatalysatoren zur ezetimib-synthese |
JP2013528374A (ja) | 2010-05-10 | 2013-07-11 | パーシード セラピューティクス リミテッド ライアビリティ カンパニー | Vla4のポリペプチド阻害剤 |
CA2798937A1 (en) | 2010-05-28 | 2011-12-01 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
EP2582799B1 (de) | 2010-06-17 | 2017-12-20 | Codexis, Inc. | Biokatalysatoren und verfahren zur synthese von (s)-3-(1-aminoethyl)-phenol |
CA2804019A1 (en) | 2010-06-28 | 2012-01-12 | Codexis, Inc. | Fatty alcohol forming acyl reductases (fars) and methods of use thereof |
WO2012003299A2 (en) | 2010-06-30 | 2012-01-05 | Codexis, Inc. | Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
US9006460B2 (en) | 2010-08-16 | 2015-04-14 | Cardiome International Ag | Process for preparing aminocyclohexyl ether compounds |
EP2606131B1 (de) | 2010-08-20 | 2017-03-08 | Codexis, Inc. | Verwendung von proteinen der glycosidhydrolase-familie 61 bei der verarbeitung von cellulose |
HUE037616T2 (hu) | 2010-12-08 | 2018-09-28 | Codexis Inc | Biokatalizátorok és eljárások armodafinil szintéziséhez |
EE05750B1 (et) | 2011-02-25 | 2015-06-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tüvi Lactobacillus gasseri MCC2 DSM 23882 ning selle kasutamine |
EP2691517A4 (de) | 2011-03-30 | 2015-04-22 | Codexis Inc | Pentosefermentierung durch einen rekombinanten mikroorganismus |
US9102963B2 (en) | 2011-04-13 | 2015-08-11 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
UA111078C2 (uk) * | 2011-05-03 | 2016-03-25 | Нестек С.А. | Гідролізат білкового субстрату і спосіб його виготовлення |
US8778652B2 (en) | 2011-06-30 | 2014-07-15 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
DK2748317T3 (en) | 2011-08-22 | 2017-07-17 | Codexis Inc | GH61 glycoside hydrolase protein variants and cofactors that enhance GH61 activity |
WO2013036861A1 (en) | 2011-09-08 | 2013-03-14 | Codexis, Inc | Biocatalysts and methods for the synthesis of substituted lactams |
WO2013048661A1 (en) | 2011-09-30 | 2013-04-04 | Codexis, Inc. | Fungal proteases |
WO2013052101A1 (en) * | 2011-10-03 | 2013-04-11 | Kelly Foods Corporation | Probiotic composition for pets and method of providing the same |
US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
WO2013074650A1 (en) | 2011-11-18 | 2013-05-23 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
WO2013096244A1 (en) | 2011-12-20 | 2013-06-27 | Codexis, Inc. | Endoglucanase 1b (eg1b) variants |
SG11201405990PA (en) | 2012-03-23 | 2014-11-27 | Codexis Inc | Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs |
US20130251829A1 (en) * | 2012-03-23 | 2013-09-26 | Mead Johnson Nutrition Company | Probiotic derived non-viable material for infection prevention and treatment |
HUE042605T2 (hu) | 2012-05-08 | 2019-07-29 | Codexis Inc | Biokatalizátorok és kémiai vegyületek hidroxilálására szolgáló eljárások |
WO2013170050A1 (en) | 2012-05-11 | 2013-11-14 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
WO2013188313A2 (en) | 2012-06-11 | 2013-12-19 | Codexis, Inc. | Fungal xylanases and xylosidases |
AU2013348272A1 (en) | 2012-11-20 | 2015-05-14 | Shell Internationale Research Maatschappij B.V. | Pentose fermentation by a recombinant microorganism |
EP2928865B1 (de) | 2012-12-07 | 2018-04-11 | Merck Sharp & Dohme Corp. | Biokatalytisches transaminierungsverfahren |
JP6618180B2 (ja) | 2012-12-21 | 2019-12-11 | コデクシス, インコーポレイテッド | キラルアミンを合成するための操作された生体触媒および方法 |
CA2898495C (en) | 2013-01-18 | 2021-06-01 | Codexis, Inc. | Engineered biocatalysts useful for carbapenem synthesis |
SI2961844T1 (sl) | 2013-02-28 | 2018-11-30 | Codexis, Inc. | Spremenjeni polipeptidi transaminaze za industrijsko biokatalizo |
CN103355405A (zh) * | 2013-04-07 | 2013-10-23 | 苏州旭优食品科技有限公司 | 一种低过敏性含乳制品的加工工艺 |
HUE055899T2 (hu) | 2013-04-18 | 2022-01-28 | Codexis Inc | Átszerkesztett fenilalanin-ammónia-liáz polipeptidek |
HUE053379T2 (hu) | 2013-11-13 | 2021-06-28 | Codexis Inc | Génmódosított imin-reduktázok és eljárások keton és amin vegyületek reduktív aminálására |
DK3145536T3 (da) | 2014-04-16 | 2022-01-03 | Codexis Inc | Modificeret tyrosinammoniaklyase |
US9708587B2 (en) | 2014-07-09 | 2017-07-18 | Codexis, Inc. | P450-BM3 variants with improved activity |
HUE053363T2 (hu) | 2014-11-25 | 2021-06-28 | Codexis Inc | Módosított iminreduktázok és eljárások keton- és aminvegyületek reduktív aminálására |
MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
HUE062016T2 (hu) | 2014-12-22 | 2023-09-28 | Codexis Inc | Humán alfa-galaktozidáz variánsok |
ES2830725T3 (es) | 2015-02-10 | 2021-06-04 | Codexis Inc | Polipéptidos cetoreductasa para la síntesis de compuestos quirales |
DK3292136T3 (da) | 2015-05-07 | 2021-03-22 | Codexis Inc | Penicillin-g-acylaser |
WO2017007547A1 (en) | 2015-07-07 | 2017-01-12 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
AU2017260355B2 (en) | 2016-05-05 | 2023-03-30 | Codexis, Inc. | Penicillin-G acylases |
EP3469088B1 (de) | 2016-06-09 | 2023-09-06 | Codexis, Inc. | Biokatalysatoren und verfahren zur hydroxylierung von chemischen verbindungen |
CA3027189A1 (en) | 2016-06-15 | 2017-12-21 | Codexis, Inc. | Engineered beta-glucosidases and glucosylation methods |
IL264686B2 (en) | 2016-08-26 | 2024-07-01 | Codexis Inc | Engineered imine reductases and methods for reversible amination of ketone and amine compounds |
WO2018129130A1 (en) | 2017-01-05 | 2018-07-12 | Codexis, Inc. | Penicillin-g acylases |
US20180223264A1 (en) | 2017-02-03 | 2018-08-09 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
EP3579867A4 (de) | 2017-02-13 | 2021-03-10 | Codexis, Inc. | Manipulierte phenylalanin-ammoniak-lyase-polypeptide |
SG11201909807TA (en) | 2017-04-24 | 2019-11-28 | Tesaro Inc | Methods of manufacturing of niraparib |
CN110831618B (zh) | 2017-04-27 | 2023-08-25 | 科德克希思公司 | 酮还原酶多肽及多核苷酸 |
JP7401902B2 (ja) | 2017-05-08 | 2023-12-20 | コデクシス, インコーポレイテッド | 遺伝子操作されたリガーゼバリアント |
WO2018231462A1 (en) | 2017-06-14 | 2018-12-20 | Codexis, Inc. | Engineered transaminase polypeptides for industrial biocatalysis |
WO2019005337A1 (en) | 2017-06-27 | 2019-01-03 | Codexis, Inc. | PENICILLIN G ACYLASES |
KR20200023455A (ko) | 2017-06-30 | 2020-03-04 | 코덱시스, 인코포레이티드 | T7 rna 폴리머라제 변이체 |
US10738286B2 (en) | 2017-06-30 | 2020-08-11 | Codexis, Inc. | T7 RNA polymerase variants |
WO2019094301A1 (en) | 2017-11-07 | 2019-05-16 | Codexis, Inc. | Transglutaminase variants |
US11535833B2 (en) | 2017-12-13 | 2022-12-27 | Glaxosmithkline Intellectual Property Development Limited | Carboxyesterase biocatalysts |
SG11202004185PA (en) | 2017-12-13 | 2020-06-29 | Codexis Inc | Carboxyesterase polypeptides for amide coupling |
CA3102968A1 (en) | 2018-06-12 | 2019-12-19 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
KR20210031933A (ko) | 2018-07-09 | 2021-03-23 | 코덱시스, 인코포레이티드 | 조작된 포스포펜토뮤타제 변이체 효소 |
WO2020014047A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered purine nucleoside phosphorylase variant enzymes |
EP3821015A4 (de) | 2018-07-09 | 2022-07-13 | Codexis, Inc. | Gentechnisch hergestellte desoxyribose-phosphat-aldolasen |
KR20210030379A (ko) | 2018-07-09 | 2021-03-17 | 코덱시스, 인코포레이티드 | 조작된 갈락토스 옥시다제 변이 효소 |
CN112673091A (zh) | 2018-07-09 | 2021-04-16 | 科德克希思公司 | 工程化泛酸激酶变体酶 |
EP3820833A4 (de) | 2018-07-12 | 2022-08-03 | Codexis, Inc. | Manipulierte phenylalanin-ammoniak-lyase-polypeptide |
WO2020028039A1 (en) | 2018-07-30 | 2020-02-06 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
EP3874033A4 (de) | 2018-10-29 | 2022-08-03 | Codexis, Inc. | Manipulierte varianten von dna-polymerase |
CA3122524A1 (en) | 2018-12-14 | 2020-06-18 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
EA202191735A1 (ru) | 2018-12-20 | 2021-11-24 | Кодексис, Инк. | Варианты альфа-галактозидазы человека |
EP4003061B1 (de) | 2019-07-23 | 2024-04-24 | FrieslandCampina Nederland B.V. | Ernährungszusammensetzung mit milchfett und immunglobulin |
KR20220106738A (ko) | 2019-08-30 | 2022-07-29 | 코덱시스, 인코포레이티드 | 조작된 리파제 변이체 |
JP2022547523A (ja) | 2019-09-12 | 2022-11-14 | コデクシス, インコーポレイテッド | 10-アセチル-3,7-ジヒドロキシフェノキサジンに対するペルオキシダーゼ活性 |
US20220372542A1 (en) | 2019-10-02 | 2022-11-24 | Abbott Diabetes Care Inc. | Detection of analytes by protein switches |
AU2020408066A1 (en) | 2019-12-20 | 2022-06-30 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
IL296841A (en) | 2020-04-10 | 2022-11-01 | Codexis Inc | Transaminase transaminase polypeptides |
BR112023003606A2 (pt) | 2020-08-28 | 2023-03-28 | Codexis Inc | Protease recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma protease recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, e, uso |
JP2023539634A (ja) | 2020-08-28 | 2023-09-15 | コデクシス, インコーポレイテッド | 操作されたアミラーゼバリアント |
US20220186231A1 (en) | 2020-12-11 | 2022-06-16 | Willow Biosciences, Inc. | Recombinant acyl activating enzyme (aae) genes for enhanced biosynthesis of cannabinoids and cannabinoid precursors |
US11898174B2 (en) | 2020-12-18 | 2024-02-13 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
CA3214973A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered guanylate kinase variant enzymes |
CA3214972A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered adenylate kinase variant enzymes |
CA3215105A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
EP4314264A1 (de) | 2021-04-02 | 2024-02-07 | Codexis, Inc. | Manipulierte cyclische gmp-amp-synthase (cgas)-varianten enzyme |
CA3227215A1 (en) | 2021-07-30 | 2023-02-02 | Trish Choudhary | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |
WO2023023621A1 (en) | 2021-08-19 | 2023-02-23 | Willow Biosciences, Inc. | Recombinant olivetolic acid cyclase polypeptides engineered for enhanced biosynthesis of cannabinoids |
WO2023069921A1 (en) | 2021-10-19 | 2023-04-27 | Epimeron Usa, Inc. | Recombinant thca synthase polypeptides engineered for enhanced biosynthesis of cannabinoids |
WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
WO2024150146A1 (en) | 2023-01-12 | 2024-07-18 | Novartis Ag | Engineered ketoreductase polypeptides |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3886288A (en) * | 1970-06-15 | 1975-05-27 | Swift & Co | Cheese manufacture using highly active proteolytic enzymes |
JPS5279086A (en) | 1975-12-25 | 1977-07-02 | Nippon Soda Co Ltd | Preparation of antibiotic tunicamycin |
JPS5279083A (en) * | 1975-12-26 | 1977-07-02 | Morinaga Milk Industry Co Ltd | Production of protein decomposed substance not having bitterness and antigen property |
JPS6041751B2 (ja) | 1976-06-22 | 1985-09-18 | ジエコ−株式会社 | デジタル電子時計 |
JPS548785A (en) | 1977-06-21 | 1979-01-23 | Kikkoman Corp | Preparation of protein hydrolyzate |
US4839281A (en) † | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
ATE84680T1 (de) † | 1987-12-23 | 1993-02-15 | Nestle Sa | Verfahren zur herstellung eines molkeeiweisshydrolysates und eines hypoallergenen nahrungsmittels. |
DD281540A5 (de) * | 1988-08-08 | 1990-08-15 | Berlin Chemie Veb | Verfahren zur herstellung von nutritiva |
ATE113441T1 (de) † | 1989-10-02 | 1994-11-15 | Sandoz Nutrition Ltd | Proteinhydrolysaten. |
JP3071877B2 (ja) † | 1991-06-27 | 2000-07-31 | 財団法人糧食研究会 | 経口寛容誘導能を有する低アレルゲン性酵素分解ペプチド組成物 |
US5952034A (en) * | 1991-10-12 | 1999-09-14 | The Regents Of The University Of California | Increasing the digestibility of food proteins by thioredoxin reduction |
ES2111625T3 (es) * | 1992-07-06 | 1998-03-16 | Nestle Sa | Agente antigastritis. |
FI94089C (fi) | 1992-12-10 | 1995-07-25 | Valio Oy | Menetelmä allergiaa aiheuttavien yhdisteiden poistamiseksi proteiinipitoisista koostumuksista |
RU2031586C1 (ru) | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения |
GB9312369D0 (en) | 1993-06-16 | 1993-07-28 | Sandoz Nutrition Ltd | Organic compounds |
WO1995014485A1 (fr) † | 1993-11-23 | 1995-06-01 | Kabushiki Kaisha Wado Doctors Group | Composition adjuvante de flore intestinale et appareil et systeme de production |
FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
-
1995
- 1995-06-14 FI FI952926A patent/FI104465B/fi not_active IP Right Cessation
-
1996
- 1996-06-11 MY MYPI96002357A patent/MY113912A/en unknown
- 1996-06-12 US US08/973,963 patent/US6506380B1/en not_active Expired - Lifetime
- 1996-06-12 BR BR9607827-8A patent/BR9607827A/pt not_active Application Discontinuation
- 1996-06-12 EP EP96918707A patent/EP0833649B2/de not_active Expired - Lifetime
- 1996-06-12 DE DE69625690T patent/DE69625690T3/de not_active Expired - Lifetime
- 1996-06-12 KR KR1019970709383A patent/KR100494741B1/ko not_active IP Right Cessation
- 1996-06-12 CA CA2224320A patent/CA2224320C/en not_active Expired - Lifetime
- 1996-06-12 SK SK1715-97A patent/SK284245B6/sk not_active IP Right Cessation
- 1996-06-12 DK DK96918707T patent/DK0833649T4/da active
- 1996-06-12 EE EE9700339A patent/EE03424B1/xx unknown
- 1996-06-12 AT AT96918707T patent/ATE230606T1/de active
- 1996-06-12 CN CNB961947527A patent/CN1154506C/zh not_active Expired - Lifetime
- 1996-06-12 ES ES96918707T patent/ES2191103T5/es not_active Expired - Lifetime
- 1996-06-12 JP JP50267197A patent/JP3983804B2/ja not_active Expired - Lifetime
- 1996-06-12 RO RO97-02328A patent/RO120243B1/ro unknown
- 1996-06-12 WO PCT/FI1996/000350 patent/WO1997000078A1/en not_active Application Discontinuation
- 1996-06-12 CZ CZ19973997A patent/CZ291904B6/cs not_active IP Right Cessation
- 1996-06-12 IL IL12257796A patent/IL122577A0/xx not_active IP Right Cessation
- 1996-06-12 PL PL96324010A patent/PL185123B1/pl unknown
- 1996-06-12 NZ NZ310478A patent/NZ310478A/xx not_active IP Right Cessation
- 1996-06-13 AR ARP960103134A patent/AR003960A1/es unknown
- 1996-06-14 ZA ZA965088A patent/ZA965088B/xx unknown
-
1997
- 1997-12-11 NO NO19975832A patent/NO321504B1/no not_active IP Right Cessation
- 1997-12-11 MX MX9710109A patent/MX9710109A/es unknown
- 1997-12-23 BG BG102144A patent/BG63153B1/bg unknown
-
1998
- 1998-09-24 HK HK98110938A patent/HK1010081A1/xx not_active IP Right Cessation
-
2002
- 2002-12-18 US US10/321,661 patent/US7172756B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO321504B1 (no) | Fremgangsmater for in vitro fremstilling av proteinhydrolysatsammensetning, oral proteinhydrolysatsammensetning og anvendelser derav. | |
Majamaa et al. | Probiotics: a novel approach in the management of food allergy | |
Eslami et al. | Probiotics function and modulation of the immune system in allergic diseases | |
Sütas et al. | Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG–derived enzymes | |
Brouwer et al. | No effects of probiotics on atopic dermatitis in infancy: a randomized placebo‐controlled trial | |
Mine et al. | Recent advances in the understanding of egg allergens: basic, industrial, and clinical perspectives | |
RU2539514C2 (ru) | Питательная композиция, содержащая штаммы bifidobacterium longum и ослабляющая сиптомы пищевой аллергии, особенно у младенцев и детей | |
Lodinová-Žádníková et al. | Prevention of allergy in infants of allergic mothers by probiotic Escherichia coli | |
Uncuoglu et al. | Tolerance to baked and fermented cow's milk in children with IgE-mediated and non-IgE-mediated cow's milk allergy in patients under two years of age | |
US20100221226A1 (en) | Use of a Bifidobacterium Strain for Preparing a Composition for Preventing and/or Treating Allergic Manifestations | |
CN117224652A (zh) | 最新鉴定出的用于诱导幼年哺乳动物口服耐受性的肽 | |
Isolauri | Intestinal involvement in atopic disease | |
Prioult et al. | Allergenicity of acidic peptides from bovine β-lactoglobulin is reduced by hydrolysis with Bifidobacterium lactis NCC362 enzymes | |
Xu et al. | Effect of lactic acid bacteria fermentation on cow milk allergenicity and antigenicity: A review | |
RU2174012C2 (ru) | Способы профилактики или лечения аллергии | |
AU710126C (en) | Methods of preventing or treating allergies | |
Rosetta et al. | On the role of breastfeeding in health promotion and the prevention of allergic diseases | |
Businco et al. | Food allergy and atopic dermatitis. | |
Biscola et al. | Lactic Acid Bacteria Application to Decrease Food Allergies | |
Ouwehand et al. | From hypoallergenic foods to anti-allergenic foods | |
Schouten et al. | Nutrition and food allergy | |
CZ22359U1 (cs) | Hypoalergenní mléčný přípravek pro dospívající a dospělou populaci |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |